Document Detail

A review of monochromatic excimer light in vitiligo.
MedLine Citation:
PMID:  22524428     Owner:  NLM     Status:  MEDLINE    
Phototherapy is a mainstay of vitiligo treatment and has varying rates of efficacy. Narrowband ultraviolet (UV) B (NB-UVB) and UVA have been used for decades, but it is only recently that monochromatic excimer light (MEL) was developed for use in dermatology and adapted for the treatment of vitiligo. The specific 308-nm radiation wavelength is delivered in a targeted form by the xenon-chloride excimer laser and is also available in an incoherent form that is commonly referred to as the excimer lamp. MEL administered by both laser and lamp has shown efficacy superior to NB-UVB for the treatment of vitiligo and induces more changes at the cellular level than conventional UVB modalities. The excimer laser is effective in adults and children with vitiligo in all skin types as monotherapy or in combination with other established vitiligo therapeutics. Treatment regimens studied included excimer laser two to three times weekly for up to 36 weeks. Patients commonly achieved > 75% repigmentation. The laser has also been used in combination with topical corticosteroids, calcineurin inhibitors and vitamin D analogues, as well as surgery, thus further expanding treatment options for patients with vitiligo. The excimer lamp has been used for treatments one to three times a week for up to 24 weeks and was found to be equal to excimer laser in a head-to-head comparison. It has also been used in combination with topical corticosteroids and oral vitamin E. Both MEL modalities have a limited adverse side-effect profile. Long-term effects are yet to be determined; however, based on available data on UVB phototherapy as well as the properties of MEL devices, there is probably only a minimal increased malignancy risk.
K K Park; W Liao; J E Murase
Related Documents :
22525508 - The effect of a mismatched center of rotation on the clinical outcomes and flexion-exte...
22865728 - Olfactory outcomes following endoscopic pituitary surgery with or without septal flap r...
22487918 - Gastrointestinal stromal tumors treatment in the imatinib era. the role of fair indicat...
22721458 - Effect of platelet-rich plasma with fibrin matrix on healing of intrasynovial flexor te...
19886318 - Comparison of gentamicin and mupirocin in the prevention of exit-site infection and per...
23019678 - Inhaled epoprostenol improves oxygenation in severe hypoxemia.
Publication Detail:
Type:  Journal Article; Review     Date:  2012-08-08
Journal Detail:
Title:  The British journal of dermatology     Volume:  167     ISSN:  1365-2133     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-28     Completed Date:  2013-01-15     Revised Date:  2014-04-08    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  468-78     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. BJD © 2012 British Association of Dermatologists.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Combined Modality Therapy / methods
Dermatologic Agents / therapeutic use
Epidemiologic Methods
Lasers, Excimer / therapeutic use*
Patient Safety
Phototherapy / instrumentation,  methods*
Skin Neoplasms / prevention & control
Skin Transplantation / methods
Vitiligo / therapy*
Reg. No./Substance:
0/Dermatologic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kb Inhibito...
Next Document:  Impact of vertical loading on the implant-bone interface.